Welcome to In vitro models by Oliveira, J. M. & Ketul, C. P.
Vol.:(0123456789) 
In vitro models 
https://doi.org/10.1007/s44164-021-00002-9
HIGHLIGHTS AND EDITORIALS
Welcome to In vitro models
J. Miguel Oliveira1,2 · Ketul C. Popat3
Received: 5 July 2021 / Revised: 8 August 2021 / Accepted: 23 August 2021 
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021
Welcome, mission and vision
The cross-disciplinary field of in vitro models has been 
attracting a great deal of attention in the last decade due to 
the need to address the paradigm-shifts in research related 
to:
• An increasing trend for “saying goodbye to flat biology”, 
i.e. introduce 3D in research methods in order to develop 
tools that can better emulate human tissues/organs and 
diseases;
• The need to reduce/eliminate extensive animal experi-
mentation.
In vitro models is a hybrid journal published by Springer 
(part of Springer Nature), and it is the first of the kind focus-
ing on research that deals with the upcoming and impact-
ful field of in vitro models. With Springer Nature, a global 
publisher dedicated to providing the best possible service 
to the whole research community, In vitro models will be 
able to reach a vast audience and target a multidisciplinary 
research community.
The In vitro models mission is to contribute to the fast 
peer-review and cross-disciplinary dissemination and foster 
the application of research and technology developments in 
the field of in vitro models. Our vision is to establish and 
become a leading scientific journal with worldwide coverage 
for the successful interdisciplinary integration of research 
knowledge and diffusion of significant findings related to the 
in vitro models research. The science related to in vitro mod-
els is currently receiving enormous interest from different 
disciplines, worldwide, from drug development and delivery, 
biofabrication, materials science, nanomedicine, microfluid-
ics, personalized medicine, biology, cancer research, and tis-
sue engineering. Therefore, we also aim to foster the growth 
of the scientific community in this field, in the coming years.
The Editors-in-chief of this new journal are Prof. J. 
Miguel Oliveira and Prof. Ketul Popat.
Prof. J. Miguel Oliveira is a biochemist, and received 
his Ph.D. in Materials Science and Technology, Knowledge 
Area of Tissue Engineering—Hybrid Materials from Uni-
versity of Minho, Braga—Portugal, in 2009. He is a Princi-
pal Investigator with Habilitation and Professor in Doctoral 
Program in Tissue Engineering, Regenerative Medicine and 
Stem Cells (TERM&SC) at University of Minho, Guima-
rães—Portugal. He is the Vice-President of I3Bs—Institute 
for Biomaterials, Biodegradables and Biomimetics (Univ. 
Minho) and Director of Pre-Clinical Research at the FIFA 
Medical Center, Estádio do Dragão, Porto, PT, since Feb. 
2013. Over the years, he has focused his work on the field 
of biomaterials for tissue engineering, nanomedicine, stem 
cells, and cell/drug delivery applications and established a 
research line within the I3Bs on 3D in vitro models. As a 
result of his proficiency, he has published so far more than 
400 scientific contributions in scientific journals with the 
referee. He has approved more than 20 patents, published 6 
books, 5 special issues in scientific journals, and more than 
100 book chapters in books with international circulation. 
He has been awarded several prizes including the prestig-
ious “Investigador FCT 2012 and Investigador FCT 2015” 
attributed by FCT (Portugal), and The Jean Leray Award 
2015 from European Society for Biomaterials for Young 
Scientists for Outstanding Contributions within the field of 
Biomaterials. He is also a member of the National Ethics 
Committee for Clinical Trials from SNS—Serviço Nacional 
de Saúde (Portugal).
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Prof. Ketul C. Popat a Professor in the Department of 
Mechanical Engineering/School of Biomedical Engineering/
School of Advanced Materials Discovery at Colorado State 
University. He is also Director of Undergraduate Programs 
in Biomedical Engineering. Prior to that, he was working 
as a Research Specialist in the Department of Physiology 
at University of California, San Francisco. His research 
expertise is in the areas of biomaterials, tissue engineer-
ing, and nanostructured surfaces for medical devices. He 
has authored over 140 peer-reviewed publications in high-
impact journals and presented his work at numerous national 
and international level conferences. He received his Ph.D. 
in Bioengineering from University of Illinois at Chicago in 
2003, M.S. in Chemical Engineering from Illinois Institute 
of Technology, Chicago, in 2000, and B.E. in Chemical 
Engineering from M. S. University in India in 1998.
The senior honorary advisors, editorial 
board, and young editorial board
The In vitro models gathers an outstanding Editorial Board 
composed of two Senior Honorary Advisors, Prof. Rui L. 
Reis and Prof. David Kaplan.
Professor Rui L. Reis, PhD, DSc, Hon. Causa MD, Hon 
Causa PhD, FBSE, FTERM, member of NAE, FAIMBE, 
FEAMBES, was born in 1967 in Porto, Portugal. He is a 
Full Professor of Tissue Engineering, Regenerative Medi-
cine, Biomaterials and Stem Cells at University of Minho 
(UMinho), Director of the 3B’s Research Group—member 
of the I3Bs – Institute for Biomaterials, Biodegradables 
and Biomimetics, and Director of the ICVS/3B’s Associ-
ate Laboratory, both of UMinho. He is also the CEO of the 
European Institute of Excellence on Tissue Engineering and 
Regenerative Medicine, the Global Past-President of the Tis-
sue Engineering and Regenerative Medicine International 
Society (TERMIS) and the Editor-in-chief of the Journal 
of Tissue Engineering and Regenerative Medicine. He is in 
the Editorial Board of several other relevant journals. He 
is a recognized World Expert in the TERM and biomateri-
als fields that has edited several books and has more 1460 
published works listed on ISI Web of Knowledge with an h 
index of 98 (1360 works and h = 102 in Scopus and 2210 
and h = 124 in Google Scholar), being also an inventor of 
around 115 patents. Based on those, he co-funded sev-
eral companies that raised important private investments. 
According to Google Scholar, his work has been cited more 
than 68,500 times. He has been awarded many important 
international prizes, including among several others differ-
ent innovation awards, the Jean Leray and George Winter 
Awards (ESB), the Clemson Award (SFB), the TERMIS-EU 
contributions to the literature Award and the TERMIS-EU 
Career Achievement Award, and in 2018 the UNESCO—
International Life Sciences Award and the IET A. F. Harvey 
Engineering Research Prize. He is a member of the National 
Academy of Engineering (USA), FBSE, FTERM, and was 
awarded 2 honouris causa degrees. He is the PI of projects 
with a budget totalizing more than 100 MEuros of which 
around 50 MEuros are U. Minho funding.
Prof. David Kaplan holds an Endowed Chair, the Stern 
Family Professor of Engineering, at Tufts University (USA). 
He is Professor & Chair of the Department of Biomedical 
Engineering and also holds faculty appointments in the 
School of Medicine, the School of Dental Medicine, Depart-
ment of Chemistry, and the Department of Chemical and 
Biological Engineering. His research focus is on biopolymer 
engineering to understand structure–function relationships, 
with emphasis on studies related to self-assembly, biomate-
rials engineering, and functional tissue engineering/regen-
erative medicine. He has published over 900 peer-reviewed 
papers, including on a variety of structural proteins. He 
directed the NIH P41 Tissue Engineering Resource Center 
(TERC) that involved Tufts University and Columbia Uni-
versity from 2004 to 2019 and continues to lead the bio-
materials core (2020–present). He serves on the editorial 
boards of numerous journals and is Editor-in-chief for ACS 
Biomaterials Science and Engineering, after serving as an 
associate editor for Biomacromolecules for 15 years. He has 
received a number of awards for teaching, was elected Fel-
low American Institute of Medical and Biological Engineer-
ing, elected to the International Academy of Medical and 
Biological Engineering, and received the Columbus Discov-
ery Medal and the Society for Biomaterials Clemson Award 
for contributions to the literature.
The Editorial Board (EB) has been set up and already 
gathers over 40 top researchers from all over the world, and 
it is expanding. The role of members of the EB involves:
• Helping the journal to attract high-quality manuscripts, 
for example by mentioning the journal to peers and at 
conferences;
• Submitting own research and/or writing occasional 
reviews for the journal;
• Suggesting topics and authors for commissioned reviews 
and commentaries;
• Providing feedback and suggesting improvements for the 
journal;
• Reviewing manuscripts for the journal (no more than 3 a 
year).
In addition, a panel of Early Career Board Members is 
currently being established. The In vitro models will open a 
call for other members to join the early career panel, target-
ing researchers at the early stage in their careers (less than 
10 years after completion of their PhD).
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Aims, scope, and topics
The In vitro models aims to become a leading journal among 
the top multidisciplinary journals covering all aspects of 
in vitro models’ research, which also includes a broad spec-
trum of topics related to the interface of biomaterials sci-
ence, chemistry, physics, engineering, informatics, nano-
technology, pharma, medicine, and biology.
The scope of the In vitro models is related to expand-
ing the field of in vitro cell/tissue/organs culture models. A 
search in the PUBMED database (July 1, 2021) using the 
keyword “In vitro models” shows that this field has signifi-
cantly grown as reflected by the number yearly published 
works; i.e., since the year 2000 until 2020, the number 
of publications increased from 6599/year to 29,411/year, 
respectively.
This new journal will provide a specialized forum for the 
publication of ideas/concepts, and significant and original 
work related to experimental and theoretical studies on fun-
damental and applied inter- and multi-disciplinary research 
dealing with in vitro models, with a particular focus on the 
following topics:
• In vitro models;
• New perspectives in in vitro tissue models research;
• Complementary and alternative models to animal experi-
mentation;
• Cell culturing methods (e.g., 2D, 3D, and 4D cell cul-
ture);
• Ex vivo models;
• Biomaterials as extracellular matrix;
• Drug discovery and development;
• Bioprinting;






• In silico models;






• Extracellular vesicles development and characterization;
• New in vitro assays development for regulatory approv-
als;
• Translational research.
The main list of keywords includes the following: 2D, 
3D and 4D models; 3D cell culture; Dynamic culturing; 
Extracellular matrix; In vitro models; In silico models; 
Biomaterials; Biofluids; Biology; Biological compounds; 
Bioprinting; Bioreactors, Biomedical science; Cell engi-
neering; Drug development; Ex vivo models; Extracellu-
lar vesicles development and characterization; Methods; 
Modelling; Microfluidics; Pharma; Organoids, Organ-on-
a-chip; Drug testing; Nanomedicine; New in vitro assays 
development for regulatory approvals; Tissue engineer-
ing; Theoretical studies; Diseases; Tissue models; Tumor 
models; Stem cells; Scaffolds; Spheroids, Simulation; 
Standardization.
Types of articles
The In vitro models journal will peer-review and publish 
different types of articles, including (i) Original Articles 
consisting of full-length accounts of original research that 
provide a comprehensive report of original research pre-
senting a significant advance of lasting impact, related to 
the topics covered by the journal; (ii) Rapid Communica-
tions, where authors must provide short articles report-
ing outstanding, new, and timely developments/contribu-
tions within the scope of the Journal. Length should be 
no longer than 5 journal pages or 4500 words, including 
figures; (iii) Reviews that critically evaluate an existing 
work of multiple groups in a field or topic related to the 
scope of the journal. It should reflect the current state-of-
the-art and be of general interest to the readership. The 
structure and length should follow the standard Springer 
instructions for authors. Length is flexible (6–20 or more 
pages) and a maximum of 400 references; (iv) Concepts 
where authors should provide a brief paper with key 
details about new ideas, research concepts, or findings, 
related to in vitro models, that are of particular interest to 
a vast audience, and that merit further exploration. Length 
should be 3–5 pages; (v) Methods focusing on rapidly 
developing laboratory techniques and disruptive meth-
ods/modelling of significance in the in vitro models’ field. 
Length should be no longer than 5 journal pages or 4500 
words, including figures; (vi) Opinion Papers by invita-
tion from the Editor(s)-in-Chief. Authors should report 
original and personal views on a given subject. It should 
be based on published data, should not expand on opinions 
by others, and should be written in a logical, profession-
ally sound, and convincing way. Thus, authors should out-
line, and craft selected arguments by bringing original and 
groundbreaking ideas and imaginative research solutions. 
Length should be no longer than 5 pages; (vii) Highlights 
by invitation from the Editor(s)-in-Chief. Authors should 
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report/discuss a particular and impactful research finding. 
It must contain a brief abstract of ~ 150 words and max of 
up to 10 references. Highlights also include a graphical 
image. Length should be 2–3 pages; and (viii) Editorials 
to be submitted by the Editor(s)-in-Chief or other members 
of the Editorial board. Typical length should be 1–2 pages.
Relevance and potential impact
The In vitro models aims to represent and publish research 
to target a multidisciplinary community. The audience com-
prises the following: biologists, biomedical engineers, chem-
ists and biochemists, physicists, information technologists, 
materials and nanotechnology scientists, pharma research-
ers, regulators, and medical doctors. As aforementioned, the 
new journal covers an expanding and impactful area with 
increasing funding. The essence of the journal is to pub-
lish high-quality papers and disseminate findings and new 
standardized methods, but also to be a platform for gathering 
different experts and foster brainstorming across disciplinary 
bounds to generate new ideas and collaborations, and ulti-
mately have a broad and long-lasting impact.
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